Foh-lik J. Leong
Singapore, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 03, 2020
Comparative performance of isometric and isotonic quadriceps strength testing in total knee arthroplasty.
Journal: Musculoskeletal science & practice
Published: May 07, 2018
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.
Journal: Antimicrobial agents and chemotherapy
Published: April 26, 2017
A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.
Journal: Nature
Published: November 27, 2016
Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.
Journal: The New England journal of medicine
Published: September 23, 2016
Cryptosporidiosis Drug Discovery: Opportunities and Challenges.
Journal: ACS infectious diseases
Published: September 15, 2016
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Journal: Antimicrobial agents and chemotherapy
Published: August 20, 2014
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Journal: Antimicrobial agents and chemotherapy
Published: August 13, 2014
Spiroindolone KAE609 for falciparum and vivax malaria.
Journal: The New England journal of medicine
Published: July 31, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026